Skip to main content
Premium Trial:

Request an Annual Quote

Revenues Jump, Losses Shrink for Gene Logic in Q2

NEW YORK, July 29-Gene Logic today reported a steep hike in revenue and halved net losses for the first quarter of 2002.

 

For the reporting period ending June 30, 2002, company losses were $4.4 million, or $0.16 per share, down from $9.4 million or $0.35 per share in the equivalent period in 2001.

 

At the end of the quarter, company revenues were $14.1 million, an increase of 46 percent over the $9.6 million reported in the second quarter of the previous year.

 

Revenues were boosted by subscriptions to the company's GeneExpress database, including a new agreement with Shering-Plough.

 

However, Gene Logic also warned that it expected revenue growth to slow during the rest of the year, due to a slowdown in new customers.

 

The company said that it held cash and cash equivalents worth $180 million as of June 30, 2002.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.